New ApoGlyx results demonstrate that RG100204 is effective in reducing organ damage in a preclinical model of bacterial sepsis.
There is currently no specific treatment for sepsis, the body’s overreaction to infection that often causes severe organ damage, and death. According to the Global Sepsis Alliance, 47 to 50 million people are affected by sepsis annually, and more than 11 million of these patients die, even though sepsis is often not mentioned specifically on death certificates.
In a study conducted at the William Harvey Research Institute in London, ApoGlyx obtained results demonstrating effective reduction of organ damage, by the lead compound RG100204.
“The unique observation that we made with RG100204 was that it can improve heart function, and reduce damage to further vital organs, even when the compound was given up to three hours after the induction of sepsis! We have never tried a late administration of a drug at 3h after the onset of sepsis, so the finding that RG100204 is still effective when given at this late stage is impressive”, says Professor Christoph Thiemermann, a renowned expert in the field of sepsis.
Encouraged by the new results in the pre-clinical sepsis model, ApoGlyx is now looking to raise new capital to bring this novel approach forward to first-in-human clinical trials.